- Report
- September 2023
- 107 Pages
Asia Pacific
From €3293EUR$3,450USD£2,759GBP
- Report
- September 2023
- 101 Pages
North America
From €2815EUR$2,950USD£2,359GBP
- Report
- September 2023
- 194 Pages
Global
From €4724EUR$4,950USD£3,958GBP
- Report
- March 2021
- 137 Pages
Global
From €4676EUR$4,900USD£3,918GBP
- Report
- March 2025
- 92 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2024
- 112 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2023
- 99 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- April 2023
- 91 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- October 2023
- 146 Pages
Global
From €3367EUR$3,528USD£2,821GBP
€3961EUR$4,150USD£3,318GBP
- Report
- July 2022
- 40 Pages
Japan
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
Argentina
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
Poland
From €1432EUR$1,500USD£1,199GBP
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
United Kingdom
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
Vietnam
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
United States
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
South Korea
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
Russia
From €1432EUR$1,500USD£1,199GBP
- Report
- July 2022
- 40 Pages
Ireland
From €1432EUR$1,500USD£1,199GBP

The Viral Vector market is a subset of the biotechnology industry that focuses on the development and production of viral vectors for gene therapy. Viral vectors are modified viruses that are used to deliver genetic material into cells, allowing for the expression of a desired gene. This technology has been used to treat a variety of diseases, including cancer, genetic disorders, and infectious diseases.
Viral vectors are produced through a variety of methods, including recombinant DNA technology, synthetic biology, and cell-based systems. The production of viral vectors requires specialized equipment and expertise, making it a highly specialized field.
The Viral Vector market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Novartis, Merck, Pfizer, AstraZeneca, and Sanofi. Additionally, there are a number of smaller companies that specialize in the production of viral vectors, such as Viralgen, Oxford BioMedica, and Vigene Biosciences. Show Less Read more